HC Wainwright Issues Positive Forecast for IOVA Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Iovance Biotherapeutics in a research report issued on Tuesday, September 29th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.09) per share for the quarter, up from their prior estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.24) EPS.

IOVA has been the topic of a number of other research reports. UBS Group increased their target price on Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research note on Thursday, August 20th. Mizuho upped their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Robert W. Baird set a $6.00 target price on Iovance Biotherapeutics in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock opened at $14.22 on Thursday. Iovance Biotherapeutics has a 1 year low of $1.76 and a 1 year high of $15.30. The firm has a market cap of $6.44 billion, a PE ratio of -19.48 and a beta of 0.75. The company has a 50 day simple moving average of $8.35 and a two-hundred day simple moving average of $5.48.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $99.31 million for the quarter, compared to analyst estimates of $87.83 million. During the same quarter in the prior year, the firm posted ($0.33) EPS. Iovance Biotherapeutics’s revenue was up 65.7% on a year-over-year basis.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several hedge funds have recently made changes to their positions in the business. KBC Group NV bought a new position in Iovance Biotherapeutics in the 1st quarter worth $34,000. Sanctuary Advisors LLC purchased a new position in shares of Iovance Biotherapeutics during the first quarter valued at about $38,000. Fifth Third Bancorp purchased a new position in shares of Iovance Biotherapeutics during the first quarter valued at about $39,000. Ceera Investments LLC bought a new position in Iovance Biotherapeutics in the first quarter worth about $44,000. Finally, First National Bank & Trust Co. of Newtown bought a new position in Iovance Biotherapeutics in the second quarter worth about $51,000. 77.03% of the stock is owned by hedge funds and other institutional investors.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Higher revenue outlook supports the bull case. Iovance’s increased FY2026 revenue guidance is the main catalyst behind the recent advance, signaling stronger expectations for product demand and commercial execution. IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
• Positive Sentiment: Analysts are improving earnings expectations. Zacks Research raised its FY2026 EPS forecast to a loss of $0.55 from $0.56, FY2027 to a loss of $0.39 from $0.44, and FY2028 to a loss of $0.03 from $0.07. Several quarterly estimates were also revised higher, with Q3 2028 projected at breakeven. HC Wainwright likewise raised its estimates, maintained a “Buy” rating, and kept a $20 price target. Analyst earnings estimates for Iovance Biotherapeutics
• Positive Sentiment: Additional analyst support is helping sentiment. Wells Fargo increased its price target, while the broader consensus target was reported as rising 34.74% to $13.06. Zacks’ earnings-surprise methodology also identified IOVA as a stock investors should monitor for a potential earnings beat. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
• Neutral Sentiment: Management strengthened its medical leadership. Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer, adding global drug-development experience in T-cell therapies. The appointment is strategically supportive but is unlikely to materially affect near-term results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
• Negative Sentiment: Losses and valuation risks remain. Iovance is still expected to report a full-year loss, and the reported $13.06 consensus target is below the recent trading level. That gap could limit upside or increase volatility if revenue growth fails to meet elevated expectations.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.